Source link : https://newshealth.biz/health-news/durable-survival-outcomes-in-advanced-melanoma-with-neoadjuvant-dual-immunotherapy/
(MedPage Today) — The vast majority of patients with stage III resectable melanoma treated with neoadjuvant and adjuvant dual immunotherapy — nivolumab (Opdivo) and relatlimab (Opdualag) — remained alive and disease-free after almost 4 years… Source link : https://www.medpagetoday.com/oncology/skincancer/116494 Author : Publish date : 2025-07-14 18:45:00 Copyright for syndicated content belongs to the linked Source.
The post Durable Survival Outcomes in Advanced Melanoma With Neoadjuvant Dual Immunotherapy first appeared on News Health.
—-
Author : News Health
Publish date : 2025-07-14 18:45:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8